CClinicalTrials.gg
CompletedNCT00750165Updated Apr 9, 2019Results posted

Auto Continuous Positive Airway Pressure (CPAP) Based Energy Spectrum Analysis of Flow for Treatment of Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS)

An interventional study of SleepStyle 200 Auto Series CPAP Humidifier in Sleep Apnea, Obstructive, sponsored by Fisher and Paykel Healthcare. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-09.

Sponsored by Fisher and Paykel Healthcare · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Nasal Continuous Positive Airway Pressure (CPAP) is the standard therapy for obstructive sleep apnea hypopnea syndrome (OSAHS). This is most commonly administered as a single positive pressure that has been individualized for the patient to prevent obstructive respiratory events. However, the therapeutic pressure may vary by sleep stage and body position within a single night and may change over the course of several nights. One approach to dealing with this variability is the use of automatically adjusting CPAP that responds to patient breathing patterns with alterations in the delivered pressure. This study is designed to determine the effectiveness of using the energy spectrum analysis of flow signals to automatically adjust CPAP pressure and improve sleep variables. Thirty subjects who require CPAP will be recruited from the NYU sleep disorders center. Following diagnostic studies (either split night or full night) the subject will undergo a night of treatment with the Fisher and Paykel Healthcare AutoPAP. Efficacy of treatment will be evaluated based on normalization of sleep disordered breathing while treated with the AutoPAP.

02

Conditions studied

  • Sleep Apnea, Obstructive

Keywords

  • Obstructive Sleep Apnea
  • Humidification
  • Continuous Positive Airway Pressure
03

In context

Apnea

1,422 studies on the registry are indexed under Apnea; 159 are open to participants now.

This study's enrollment of 32 is below the median of 50 across 965 interventional studies indexed under Apnea.

Browse Apnea studies →

Lead sponsor

Fisher and Paykel Healthcare is the lead sponsor of 84 studies on the registry; 15 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 10 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • AHI >15 on the diagnostic portion of the study
  • >18 years of age

Exclusion criteria

Exclusion Criteria:

  • Significant Central Apnea
  • Congestive Heart Failure
  • Inability to give informed consent
  • Patient intolerance to CPAP
  • Anatomical or physiological conditions making CPAP therapy inappropriate
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Titration Night

    Treatment with the Fisher \& Paykel Sleep Style 200 Auto CPAP device

    Device: SleepStyle 200 Auto Series CPAP Humidifier

Interventions

  • DeviceSleepStyle 200 Auto Series CPAP Humidifier

    The device is a standard CPAP machine with a built in computer controller that incorporates software for evaluation of the flow signal obtained from the CPAP machine

    Also known as: HC254

06

What researchers measure

Primary outcomes

  1. Apnea Hypopnea Index (AHI)

    The Apnea Hypopnea Index (AHI) measure of severity of Obstructive Sleep Apnea (OSA). It is a calculation of the number of apnea events and the number of hypopnea events divided by the total sleep time. Mild OSA is characterized between 5-15 events per hour. Moderate OSA is characterized as 15-30 events per hour. Severe OSA is characterized as greater than 30 events per hour.

    Time frame: 1 night

Secondary outcomes

  1. Percent of Time With Less Than 90% Oxygen Saturation

    Oxygen saturation is a measurement of the amount of oxygen present in the blood. An oxygen saturation of less than 90% is considered low, resulting in hypoxemia. Normal blood oxygen level is considered between 95-100%.

    Time frame: 1 Night

  2. Respiratory Disturbance Index (RDI)

    Similar to AHI, the RDI is a calculation of the total number of respiratory disturbances in sleep. The calculation includes apneas and hypopneas, but also includes respiratory effort related arousals.

    Time frame: 1 Night

  3. Arousal Index (AI)

    The Arousal Index is a calculation of the frequency of awakenings per hour of sleep. The higher the number, the more awakenings per hour.

    Time frame: 1 Night

07

Results

Posted Apr 9, 2019

Participant flow

Participant flow — Overall Study
MilestoneTitration Night
Started32
Completed21
Not completed11

Outcome measures

PrimaryApnea Hypopnea Index (AHI)

The Apnea Hypopnea Index (AHI) measure of severity of Obstructive Sleep Apnea (OSA). It is a calculation of the number of apnea events and the number of hypopnea events divided by the total sleep time. Mild OSA is characterized between 5-15 events per hour. Moderate OSA is characterized as 15-30 events per hour. Severe OSA is characterized as greater than 30 events per hour.

Time frame:
1 night
Reported as:
Mean · events per hour
Apnea Hypopnea Index (AHI)
events per hourTitration Night
Apnea Hypopnea Index (AHI)2.4 (0.0 to 8.6)
SecondaryPercent of Time With Less Than 90% Oxygen Saturation

Oxygen saturation is a measurement of the amount of oxygen present in the blood. An oxygen saturation of less than 90% is considered low, resulting in hypoxemia. Normal blood oxygen level is considered between 95-100%.

Time frame:
1 Night
Reported as:
Mean · percentage of total sleep time
Percent of Time With Less Than 90% Oxygen Saturation
percentage of total sleep timeTitration Night
Percent of Time With Less Than 90% Oxygen Saturation1.4 (0 to 24.7)
SecondaryRespiratory Disturbance Index (RDI)

Similar to AHI, the RDI is a calculation of the total number of respiratory disturbances in sleep. The calculation includes apneas and hypopneas, but also includes respiratory effort related arousals.

Time frame:
1 Night
Reported as:
Mean · events per hour
Respiratory Disturbance Index (RDI)
events per hourTitration Night
Respiratory Disturbance Index (RDI)7.1 (1.5 to 13.2)
SecondaryArousal Index (AI)

The Arousal Index is a calculation of the frequency of awakenings per hour of sleep. The higher the number, the more awakenings per hour.

Time frame:
1 Night
Reported as:
Mean · events per hour
Arousal Index (AI)
events per hourTitration Night
Arousal Index (AI)16.2 (4.9 to 32.9)

Adverse events

Collected over 1 night. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Titration Night0/21 (0%)0/21 (0%)6/21 (28.6%)
Most frequent other events
Most frequent other events
EventTitration Night
Disruption of Sleep Due to Lab EnvironmentInvestigations4/21
Mask DiscomfortRespiratory, thoracic and mediastinal disorders1/21
Difficulty Exhaling Due to PressureRespiratory, thoracic and mediastinal disorders1/21

Baseline characteristics

Age, Continuous
Age, Continuous(years)Titration Night
Mean51 (29 to 76)
Sex: Female, Male
Sex: Female, Male(Participants)Titration Night
Female0
Male21
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Titration Night
Region of Enrollment
Region of Enrollment(participants)Titration Night
United States21
08

Study locations

1 site
  • NYU Sleep Disorders Center
    New York, New York 10016, United States
09

References and documents

Publications

  • Norman RG, Rapoport DM, Ayappa I. Detection of flow limitation in obstructive sleep apnea with an artificial neural network. Physiol Meas. 2007 Sep;28(9):1089-100. doi: 10.1088/0967-3334/28/9/010. Epub 2007 Sep 5. PubMed 17827656 ↗

Related links

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 9, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00750165
Lead sponsor
Fisher and Paykel Healthcare
Responsible party
Sponsor
First posted
Sep 10, 2008
Start date
May 2007
Primary completion
Jan 2008
Completion
Jan 2008
Results posted
Apr 9, 2019
Last update
Apr 9, 2019

Study contacts

David M Rapoport, MD
principal investigator · NYU School of Medicine

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion